Aug. 20 at 11:17 AM
$OCUL as optimistic as I am about the the prospects for Axpaxli, I think there is zero chance for an acquisition of the Company before the results of SOL-1 are announced. KOD surged to a valuation of
$8 billion in advance of their P3 results only to see the trial fail. That is too fresh in the minds of potential acquirers. I think it’s going to require at least
$6 billion to acquire OCUL. No one is going to be willing to take that risk without knowing the results of SOL-1.
That being said, with 95%+ of the stock in the hands of institutions, I think we will see a nice run up as we approach SOL-1 results. I was able to book a 7 figure profit on the run up in 2020 and plan to take more profits in the next 6 months. I plan to sell 1/3 of my remaining investment, originally acquired in the spring of 2019, when the share price approaches
$20/share.
